Pharmafile Logo

neurostatins

- PMLiVE

NICE set to knock-back Amgen’s myeloma treatment Kyprolis

Cites uncertainty in clinical and cost-effectiveness analyses

Bristol Myers Squibb logo

BMS wins early UK access for Opdivo in Hodgkin’s lymphoma

Cancer treatment approved by the MHRA for use before EU licence in place

- PMLiVE

‘Hard’ Brexit could mean a longer wait for new drugs, says report

Warns of deprioritised status if negotiators fail to secure access to the single market

- PMLiVE

UK to cut wait to innovative treatments by four years

Proposals in the Accelerated Access Review aim to speed up access to innovation

Eli Lilly HQ

Lilly promises solanezumab news in Alzheimer’s ‘before year-end’

If anti-amyloid drug proves effective, sales could reach $7.5bn according to analysts

- PMLiVE

Halesway changes name to FCB Halesway

Move aligns agency more closely with its parent company FCB Health

Bristol-Myers Squibb (BMS) building

NICE turns down Opdivo but offers CDF hope

Wants more cost-effectiveness data to be gathered

- PMLiVE

NICE rejects Imbruvica for non-Hodgkin’s lymphoma

Draft guidance cites insufficient cost-effectiveness evidence for J&J’s drug

National Institute for Health and Care Excellence NICE logo

NICE to create fast track for most cost-effective new drugs

Proposes accelerated appraisal process for drugs with QALY of £10,000 or less

- PMLiVE

At current progress, 2025 Alzheimer’s target ‘unlikely to be reached’

Drug development and diagnosis process requires shake-up to create effective therapies

- PMLiVE

Health activators lack confidence in primary healthcare

Survey finds patient decision-makers increasingly turning to non-traditional sources

- PMLiVE

Regional NHS pulmonary rehabilitation video campaign launched

Aims to boost referral rates among GPs in the north east of England

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links